Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis
Autor: | Mark B. Faries, Ahmed Dehal, Trevan D Fischer, Stacey L. Stern, Daniel W. Nelson, Anton J. Bilchik, Amanda N Graff-Baker |
---|---|
Rok vydání: | 2019 |
Předmět: |
Adult
Male Oncology medicine.medical_specialty Matched-Pair Analysis Systemic therapy 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Surgical oncology Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Stage (cooking) Melanoma Survival rate Neoplasm Staging Retrospective Studies business.industry Hazard ratio Metastasectomy Retrospective cohort study Middle Aged Prognosis Combined Modality Therapy Survival Rate 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology Surgery business Follow-Up Studies |
Zdroj: | Annals of Surgical Oncology. 26:4610-4618 |
ISSN: | 1534-4681 1068-9265 |
DOI: | 10.1245/s10434-019-07487-5 |
Popis: | Although resection historically played a prominent role in the treatment of metastatic melanoma, recent advances have altered the therapeutic landscape, and potentially the role of surgery. We examined surgical selection and metastasectomy outcomes before and after the onset of the effective drug therapy era. Patients with stage IV melanoma were identified and characterized by treatment era (either 1965–2007 or 2008–2015) and by systemic therapy agents. BRAF and/or MEK inhibitors, as well as checkpoint inhibitors, were included as modern agents. Selection factors for metastasectomy were examined by era. A matched-pair analysis of outcomes of surgical and non-surgical patients receiving modern systemic agents was performed. Among 2353 eligible patients, 1065 (45.2%) underwent surgical treatment. Factors associated with selection for metastasectomy in the early era included female sex, no prior stage III disease, single-organ involvement, and M1a (vs. M1c) disease (all p |
Databáze: | OpenAIRE |
Externí odkaz: |